Amber Hoberg
Psychiatric/Mental Health · Hillsboro, ORNPI 1003122532
Payments from drug & device makers
Across 2,703 payments — averaging $687.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$923K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$285K
- Neurocrine Biosciences, Inc.$244K
- E.r. Squibb & Sons, L.L.C.$158K
- Axsome Therapeutics, Inc.$84K
- Acadia Pharmaceuticals Inc$46K
- plus $118K from 20 others
What the payments were for
- Consulting fees$274,85315%
- Speaking & faculty fees$1,278,05069%
- Travel & lodging$243,96313%
- Food & beverage$60,6843%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1,124 | $923,176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 503 | $285,397 |
| Neurocrine Biosciences, Inc. | 322 | $243,860 |
| E.r. Squibb & Sons, L.L.C. | 165 | $157,944 |
| Axsome Therapeutics, Inc. | 145 | $83,552 |
| Acadia Pharmaceuticals Inc | 147 | $45,643 |
| Alkermes, Inc. | 61 | $34,181 |
| Boehringer Ingelheim | 36 | $32,238 |
| Otsuka America Pharmaceutical, Inc. | 73 | $17,005 |
| Avanir Pharmaceuticals, Inc. | 23 | $9,341 |
| Indivior Inc. | 14 | $8,494 |
| Bioxcel Therapeutics, Inc. | 11 | $6,248 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $5,661 |
| Biogen | 5 | $3,269 |
| AbbVie | 32 | $629 |
| Sunovion Pharmaceuticals Inc. | 7 | $316 |
| Johnson & Johnson | 4 | $210 |
| USWM, LLC | 3 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| Vanda Pharmaceuticals Inc. | 4 | $85 |
| Lundbeck LLC | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Corium, LLC | 2 | $44 |
| Sage Therapeutics, LLC | 1 | $27 |
| Mylan Specialty L.p. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$386,118
- Austedo XR$332,303
- CAPLYTA$278,585
- INGREZZA$239,295
- UZEDY$176,574
- COBENFY$138,188
- Auvelity$81,259
- LYBALVI$77,504
- ARISTADA$53,932
- NUPLAZID$42,703
- NUEDEXTA$14,603
- ARISTADA INITIO$13,339
- REXULTI$10,001
- PERSERIS$8,258
- IGALMI$6,095
- ABILIFY MAINTENA$4,585
- INVEGA SUSTENNA$240
- VRAYLAR$125
- LUCEMYRA$113
- INVEGA TRINZA$110
How this compares
$1,857,701 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 34 | $196,547 |
| IngrezzaValbenazine Tosylate | 18 | $145,515 |
| RexultiBrexpiprazole | 88 | $121,414 |
| UzedyRisperidone | 47 | $116,471 |
| Austedo XrDeutetrabenazine | 12 | $88,966 |
| AristadaAripiprazole Lauroxil | 20 | $67,293 |
| Invega SustennaPaliperidone Palmitate | 19 | $66,244 |
| CaplytaLumateperone Tosylate | 34 | $54,765 |
| VraylarCariprazine Hcl | 36 | $52,388 |
| NuedextaDextromethorphan Hbr/Quinidine | 32 | $45,590 |
| AuvelityDextromethorphan Hbr/Bupropion | 40 | $32,350 |
| TrintellixVortioxetine Hydrobromide | 47 | $20,551 |
| Naltrexone Hcl | 95 | $20,471 |
| Divalproex Sodium ErDivalproex Sodium | 148 | $15,805 |
| Chlorpromazine Hcl | 42 | $14,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy, Austedo Xr | $923,176 | $401,98593 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $243,860 | $145,51518 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17,005 | $121,41488 claims |
| Alkermes, Inc.Aristada | $34,181 | $67,29320 claims |
| Johnson & JohnsonInvega Sustenna | $210 | $66,24419 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $285,397 | $54,76534 claims |
| AbbVieVraylar | $629 | $52,38836 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $9,341 | $45,59032 claims |
| Axsome Therapeutics, Inc.Auvelity | $83,552 | $32,35040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Other psychiatric/mental health in Hillsboro
- Carmen KosicekHillsboro$539K
- Crystal HigbeHillsboro$5K
- Shannon EatonHillsboro$2K
- Christina FuchsHillsboro$1K
- Tina Matthews-HayesPortland$787K
- Johnni CanslerPortland$529K
- Jill CarterPortland$416K
- James AkinsEugene$137K
- William BettsEugene$41K
- Michelle VoegelsPortland$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.